Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2023 Filed Feb 14, 2023 21:46 UTC |
Jonsson PatrikEVP&Pres, LLY Imm, LLY USA&CCO
|
GrantRestricted Stock Unit · Derivative | 4,124 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000053 · wf-form4_167641114634089.xml · derivative · entry 3 Jonsson Patrik · CIK 0001786054 · EVP&Pres, LLY Imm, LLY USA&CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,124 Underlying: Common Stock · 4,124 shares Expires 2024-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:46 UTC |
Jonsson PatrikEVP&Pres, LLY Imm, LLY USA&CCO
|
GrantCommon Stock | 7,886 | $345.12 | $2,721,616.32 |
DisclosureSEC source: 0000059478-23-000053 · wf-form4_167641114634089.xml · nonDerivative · entry 1 Jonsson Patrik · CIK 0001786054 · EVP&Pres, LLY Imm, LLY USA&CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,941 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:49 UTC |
Mason Michael BEVP & Pres., Lilly Diabetes
|
GrantRestricted Stock Unit · Derivative | 3,490 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000055 · wf-form4_167641129919422.xml · derivative · entry 3 Mason Michael B · CIK 0001799419 · EVP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,490 Underlying: Common Stock · 3,490 shares Expires 2024-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:49 UTC |
Mason Michael BEVP & Pres., Lilly Diabetes
|
GrantCommon Stock | 8,023 | $345.12 | $2,768,897.76 |
DisclosureSEC source: 0000059478-23-000055 · wf-form4_167641129919422.xml · nonDerivative · entry 1 Mason Michael B · CIK 0001799419 · EVP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,284 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:52 UTC |
Norton JohnaEVP, Global Quality
|
GrantRestricted Stock Unit · Derivative | 1,268 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000057 · wf-form4_167641155807782.xml · derivative · entry 5 Norton Johna · CIK 0001702471 · EVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,268 Underlying: Common Stock · 1,268 shares Expires 2024-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:52 UTC |
Norton JohnaEVP, Global Quality
|
GrantCommon Stock | 2,507 | $345.12 | $865,215.84 |
DisclosureSEC source: 0000059478-23-000057 · wf-form4_167641155807782.xml · nonDerivative · entry 1 Norton Johna · CIK 0001702471 · EVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,908 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:01 UTC |
Ricks David ADirector · President, Chair, and CEO
|
GrantRestricted Stock Unit · Derivative | 29,611 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000061 · wf-form4_167641201578324.xml · derivative · entry 6 Ricks David A · CIK 0001538604 · Director · President, Chair, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,611 Underlying: Common Stock · 29,611 shares Expires 2024-02-01 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:01 UTC |
Ricks David ADirector · President, Chair, and CEO
|
GrantCommon Stock | 56,208 | $345.12 | $19,398,504.96 |
DisclosureSEC source: 0000059478-23-000061 · wf-form4_167641201578324.xml · nonDerivative · entry 2 Ricks David A · CIK 0001538604 · Director · President, Chair, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443,751 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:55 UTC |
Pusey Leigh AnnEVP, Corp. Affairs & Comm.
|
GrantRestricted Stock Unit · Derivative | 1,744 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000059 · wf-form4_167641169507148.xml · derivative · entry 2 Pusey Leigh Ann · CIK 0001708919 · EVP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,744 Underlying: Common Stock · 1,744 shares Expires 2024-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:55 UTC |
Pusey Leigh AnnEVP, Corp. Affairs & Comm.
|
GrantCommon Stock | 3,681 | $345.12 | $1,270,386.72 |
DisclosureSEC source: 0000059478-23-000059 · wf-form4_167641169507148.xml · nonDerivative · entry 1 Pusey Leigh Ann · CIK 0001708919 · EVP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,641 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:04 UTC |
Skovronsky DanielEVP, CS&MO & Pres., LRL
|
GrantRestricted Stock Unit · Derivative | 9,941 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000063 · wf-form4_167641225388328.xml · derivative · entry 3 Skovronsky Daniel · CIK 0001741474 · EVP, CS&MO & Pres., LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,941 Underlying: Common Stock · 9,941 shares Expires 2024-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:04 UTC |
Skovronsky DanielEVP, CS&MO & Pres., LRL
|
GrantCommon Stock | 18,388 | $345.12 | $6,346,066.56 |
DisclosureSEC source: 0000059478-23-000063 · wf-form4_167641225388328.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · EVP, CS&MO & Pres., LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,587 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:07 UTC |
Van Naarden JacobEVP and CEO Loxo@Lilly
|
GrantCommon Stock | 2,407 | $345.12 | $830,703.84 |
DisclosureSEC source: 0000059478-23-000065 · wf-form4_167641243711205.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · EVP and CEO Loxo@Lilly 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,374 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:10 UTC |
Weems AlonzoEVP, ERM & CECO
|
GrantCommon Stock | 2,422 | $345.12 | $835,880.64 |
DisclosureSEC source: 0000059478-23-000067 · wf-form4_167641257731994.xml · nonDerivative · entry 1 Weems Alonzo · CIK 0001869672 · EVP, ERM & CECO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,922 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:12 UTC |
White Anne E.EVP & Pres, Lilly Neuroscience
|
GrantRestricted Stock Unit · Derivative | 4,124 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000069 · wf-form4_167641273108663.xml · derivative · entry 4 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,124 Underlying: Common Stock · 4,124 shares Expires 2024-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:12 UTC |
White Anne E.EVP & Pres, Lilly Neuroscience
|
SaleCommon Stock | 2,500 | $342.76 | $856,900.00 |
DisclosureSEC source: 0000059478-23-000069 · wf-form4_167641273108663.xml · nonDerivative · entry 2 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,426 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 2, 2022. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:12 UTC |
White Anne E.EVP & Pres, Lilly Neuroscience
|
GrantCommon Stock | 8,562 | $345.12 | $2,954,917.44 |
DisclosureSEC source: 0000059478-23-000069 · wf-form4_167641273108663.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,926 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:19 UTC |
Yuffa IlyaEVP & President, LLY Int'l
|
GrantRestricted Stock Unit · Derivative | 3,702 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000071 · wf-form4_167641314104117.xml · derivative · entry 2 Yuffa Ilya · CIK 0001826001 · EVP & President, LLY Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,702 Underlying: Common Stock · 3,702 shares Expires 2024-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:19 UTC |
Yuffa IlyaEVP & President, LLY Int'l
|
GrantCommon Stock | 1,350 | $345.12 | $465,912.00 |
DisclosureSEC source: 0000059478-23-000071 · wf-form4_167641314104117.xml · nonDerivative · entry 1 Yuffa Ilya · CIK 0001826001 · EVP & President, LLY Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,974 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:23 UTC |
Zakrowski Donald ASVP, Finance, & CAO
|
GrantCommon Stock | 1,904 | $345.12 | $657,108.48 |
DisclosureSEC source: 0000059478-23-000073 · wf-form4_167641337639907.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · SVP, Finance, & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,178 Read SEC document |
| February 08, 2023 Filed Feb 14, 2023 22:01 UTC |
Ricks David ADirector · President, Chair, and CEO
|
GiftCommon Stock | 4,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000061 · wf-form4_167641201578324.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · Director · President, Chair, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,543 F1 · shares: On February 8, 2023, the Reporting Person transferred 4,200 shares of Eli Lilly and Company common stock to a spousal lifetime access trust, of which the Reporting Person's wife is the trustee and the Reporting Person's wife and children are beneficiaries. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:41 UTC |
Ricks David ADirector · President, Chair, and CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 47,786 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000029 · wf-form4_167546046254164.xml · derivative · entry 6 Ricks David A · CIK 0001538604 · Director · President, Chair, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,786 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:41 UTC |
Ricks David ADirector · President, Chair, and CEO
|
Tax withholdingCommon Stock | 21,359 | $344.15 | $7,350,699.85 |
DisclosureSEC source: 0000059478-23-000029 · wf-form4_167546046254164.xml · nonDerivative · entry 2 Ricks David A · CIK 0001538604 · Director · President, Chair, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,743 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:41 UTC |
Ricks David ADirector · President, Chair, and CEO
|
Exercise / conversionCommon Stock | 47,786 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000029 · wf-form4_167546046254164.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · Director · President, Chair, and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:45 UTC |
Hakim AnatEVP, GC & Secretary
|
Exercise / conversionRestricted Stock Unit · Derivative | 7,646 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000031 · wf-form4_167546071347318.xml · derivative · entry 3 Hakim Anat · CIK 0001685556 · EVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,646 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:45 UTC |
Hakim AnatEVP, GC & Secretary
|
Tax withholdingCommon Stock | 3,393 | $344.15 | $1,167,700.95 |
DisclosureSEC source: 0000059478-23-000031 · wf-form4_167546071347318.xml · nonDerivative · entry 2 Hakim Anat · CIK 0001685556 · EVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,117 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:45 UTC |
Hakim AnatEVP, GC & Secretary
|
Exercise / conversionCommon Stock | 7,646 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000031 · wf-form4_167546071347318.xml · nonDerivative · entry 1 Hakim Anat · CIK 0001685556 · EVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:48 UTC |
Jonsson PatrikEVP&Pres, LLY Imm, LLY USA&CCO
|
Exercise / conversionRestricted Stock Unit · Derivative | 6,690 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000033 · wf-form4_167546086780975.xml · derivative · entry 4 Jonsson Patrik · CIK 0001786054 · EVP&Pres, LLY Imm, LLY USA&CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,690 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:48 UTC |
Jonsson PatrikEVP&Pres, LLY Imm, LLY USA&CCO
|
Tax withholdingCommon Stock | 2,997 | $344.15 | $1,031,417.55 |
DisclosureSEC source: 0000059478-23-000033 · wf-form4_167546086780975.xml · nonDerivative · entry 2 Jonsson Patrik · CIK 0001786054 · EVP&Pres, LLY Imm, LLY USA&CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,055 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:48 UTC |
Jonsson PatrikEVP&Pres, LLY Imm, LLY USA&CCO
|
Exercise / conversionCommon Stock | 6,690 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000033 · wf-form4_167546086780975.xml · nonDerivative · entry 1 Jonsson Patrik · CIK 0001786054 · EVP&Pres, LLY Imm, LLY USA&CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:51 UTC |
Mason Michael BEVP & Pres., Lilly Diabetes
|
Exercise / conversionRestricted Stock Unit · Derivative | 6,690 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000035 · wf-form4_167546109073306.xml · derivative · entry 4 Mason Michael B · CIK 0001799419 · EVP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,690 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:51 UTC |
Mason Michael BEVP & Pres., Lilly Diabetes
|
Tax withholdingCommon Stock | 2,935 | $344.15 | $1,010,080.25 |
DisclosureSEC source: 0000059478-23-000035 · wf-form4_167546109073306.xml · nonDerivative · entry 2 Mason Michael B · CIK 0001799419 · EVP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,261 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:51 UTC |
Mason Michael BEVP & Pres., Lilly Diabetes
|
Exercise / conversionCommon Stock | 6,690 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000035 · wf-form4_167546109073306.xml · nonDerivative · entry 1 Mason Michael B · CIK 0001799419 · EVP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:54 UTC |
Norton JohnaEVP, Global Quality
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,102 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000037 · wf-form4_167546127265548.xml · derivative · entry 6 Norton Johna · CIK 0001702471 · EVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,102 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:54 UTC |
Norton JohnaEVP, Global Quality
|
Tax withholdingCommon Stock | 941 | $344.15 | $323,845.15 |
DisclosureSEC source: 0000059478-23-000037 · wf-form4_167546127265548.xml · nonDerivative · entry 2 Norton Johna · CIK 0001702471 · EVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,401 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:54 UTC |
Norton JohnaEVP, Global Quality
|
Exercise / conversionCommon Stock | 2,102 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000037 · wf-form4_167546127265548.xml · nonDerivative · entry 1 Norton Johna · CIK 0001702471 · EVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:57 UTC |
Pusey Leigh AnnEVP, Corp. Affairs & Comm.
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,154 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000039 · wf-form4_167546142093711.xml · derivative · entry 3 Pusey Leigh Ann · CIK 0001708919 · EVP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,154 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:57 UTC |
Pusey Leigh AnnEVP, Corp. Affairs & Comm.
|
Tax withholdingCommon Stock | 1,438 | $344.15 | $494,887.70 |
DisclosureSEC source: 0000059478-23-000039 · wf-form4_167546142093711.xml · nonDerivative · entry 2 Pusey Leigh Ann · CIK 0001708919 · EVP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,960 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:57 UTC |
Pusey Leigh AnnEVP, Corp. Affairs & Comm.
|
Exercise / conversionCommon Stock | 3,154 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000039 · wf-form4_167546142093711.xml · nonDerivative · entry 1 Pusey Leigh Ann · CIK 0001708919 · EVP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:01 UTC |
Skovronsky DanielEVP, CS&MO & Pres., LRL
|
Exercise / conversionRestricted Stock Unit · Derivative | 15,675 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000041 · wf-form4_167546169517695.xml · derivative · entry 4 Skovronsky Daniel · CIK 0001741474 · EVP, CS&MO & Pres., LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,675 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:01 UTC |
Skovronsky DanielEVP, CS&MO & Pres., LRL
|
Tax withholdingCommon Stock | 7,035 | $344.15 | $2,421,095.25 |
DisclosureSEC source: 0000059478-23-000041 · wf-form4_167546169517695.xml · nonDerivative · entry 2 Skovronsky Daniel · CIK 0001741474 · EVP, CS&MO & Pres., LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,199 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:01 UTC |
Skovronsky DanielEVP, CS&MO & Pres., LRL
|
Exercise / conversionCommon Stock | 15,675 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000041 · wf-form4_167546169517695.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · EVP, CS&MO & Pres., LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:04 UTC |
White Anne E.EVP & Pres, Lilly Neuroscience
|
Exercise / conversionRestricted Stock Unit · Derivative | 7,264 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000043 · wf-form4_167546185628642.xml · derivative · entry 3 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,264 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:04 UTC |
White Anne E.EVP & Pres, Lilly Neuroscience
|
Tax withholdingCommon Stock | 3,252 | $344.15 | $1,119,175.80 |
DisclosureSEC source: 0000059478-23-000043 · wf-form4_167546185628642.xml · nonDerivative · entry 2 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,364 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:04 UTC |
White Anne E.EVP & Pres, Lilly Neuroscience
|
Exercise / conversionCommon Stock | 7,264 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000043 · wf-form4_167546185628642.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,616 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:34 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 32 | $357.74 | $11,447.68 |
DisclosureSEC source: 0000059478-23-000004 · wf-form4_167416403421081.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,738 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:37 UTC |
Fyrwald J ErikDirector
|
GrantCommon Stock | 28 | $357.74 | $10,016.72 |
DisclosureSEC source: 0000059478-23-000006 · wf-form4_167416422047828.xml · nonDerivative · entry 1 Fyrwald J Erik · CIK 0001343564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,609 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:39 UTC |
Hedley Mary LynneDirector
|
GrantCommon Stock | 28 | $357.74 | $10,016.72 |
DisclosureSEC source: 0000059478-23-000008 · wf-form4_167416436661581.xml · nonDerivative · entry 1 Hedley Mary Lynne · CIK 0001340823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:42 UTC |
LUCIANO JUAN RDirector
|
GrantCommon Stock | 40 | $357.74 | $14,309.60 |
DisclosureSEC source: 0000059478-23-000010 · wf-form4_167416451683264.xml · nonDerivative · entry 1 LUCIANO JUAN R · CIK 0001455792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,738 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:44 UTC |
JOHNSON KIMBERLY HDirector
|
GrantCommon Stock | 27 | $357.74 | $9,658.98 |
DisclosureSEC source: 0000059478-23-000012 · wf-form4_167416463446584.xml · nonDerivative · entry 1 JOHNSON KIMBERLY H · CIK 0001658089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,981 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.